Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

CALCAGNO, Andrea
First
;
D'AVOLIO, ANTONIO;BONORA, Stefano
Last
2015-01-01

Abstract

Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.
2015
11
7
1167
1176
drug-to-drug interactions; pharmacodynamic; pharmacokinetic; raltegravir; resistance
Calcagno, Andrea; D'Avolio, Antonio; Bonora, Stefano
File in questo prodotto:
File Dimensione Formato  
19 DD535-16.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 424.79 kB
Formato Adobe PDF
424.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1564107
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact